30 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
issued in connection with the December 2022 Securities Purchase Agreement.
Strengthened leadership team with appointments of Meredith Manning, M.B.A … . With our strengthened leadership team and balance sheet, we are ideally positioned to carry out our corporate strategy and, if approved, deliver a new
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
16 Aug 23
Departure of Directors or Certain Officers
9:00am
. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience.
“Matt is a highly accomplished … , and earlier in his career held senior U.S. and global commercial leadership positions at Bristol-Myers Squibb and Johnson & Johnson. In addition to his
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
10 Jul 23
Regulation FD Disclosure
4:06pm
, the hallmark symptom of PWS *Diazoxide Choline Extended Release tablets 3 | © 2023 Soleno Therapeutics
Leadership Team Anish Bhatnagar, M.D. Jim
424B5
j6ivctl6 qglbnu
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
5yn9tu97t1sqner4x5z0
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
sf4u3q
10 Jan 20
Regulation FD Disclosure
5:16pm
424B5
qm8m07pze5pbmpgw
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
c76o9otzurg
22 Oct 19
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
i9syfawpadpf
29 Apr 19
Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
4:03pm
8-K
y13 egcixrk4hxo
29 Apr 19
Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
4:03pm